CereGate, a Munich, Germany and San Diego, CA-based developer of a a new software platform for neuromodulation therapy, raised un undisclosed amount of financing from High-Tech Gründerfonds.
High-Tech Gründerfonds entered with a capital increase and convertible note.
The company intends to use the funds to accelerate development of a new software platform for neuromodulation therapy.
Led by founder and CEO Dr. Bálint Várkuti, CereGate is developing a software platform which augments the programming of such neuromodulation systems for patients enabling completely novel forms of therapy, e.g. specifically suited to combat gait problems in Parkinson’s disease. The team already completed a pilot study at clinics in Freiburg and Budapest. The software is currently being extended for applications in neuroprosthetics, stroke rehabilitation and neuromodulation programming personalization.